Article
Metabolic profiling of gemcitabine- and paclitaxel-treated immortalized human pancreatic cell lines with K-RASG12D.
Biomedical research (Tokyo, Japan) - 1 Jan 2017
Todaka Akiko, Umehara Rina, Sasaki Keiko, Serizawa Masakuni, Urakami Kenichi, Kusuhara Masatoshi, Yamaguchi Ken, Yasui Hirofumi
Abstract excerpt
The mechanisms of action of gemcitabine (GEM) and paclitaxel (PTX) have been well investigated, and shown to be the inhibition of DNA polymerase and polymerization of tubulin, respectively. Meanwhile, genomic research has revealed that mutations in the K-RAS oncogene occur in over 90% of pancreatic cancer. Oncogenic alteration rewires alternative metabolic pathways to satisfy the demands of growth. The K-RAS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.